Interleukin 11 blockade during mid to late gestation does not affect maternal blood pressure, pregnancy viability or subsequent fertility in mice
| Autor: | Evdokia Dimitriadis, Ellen Menkhorst, Amy Winship, Michelle Van Sinderen |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Blood Pressure Polyethylene Glycols Andrology 03 medical and health sciences Mice Pregnancy Placenta medicine Animals reproductive and urinary physiology Fetus business.industry Decidua Pregnancy Outcome Obstetrics and Gynecology Placentation Interleukin medicine.disease Interleukin-11 Blockade Interleukin 11 Mice Inbred C57BL 030104 developmental biology medicine.anatomical_structure Fertility Reproductive Medicine embryonic structures Female business Developmental Biology Signal Transduction |
| Zdroj: | Reproductive biomedicine online. 36(3) |
| ISSN: | 1472-6491 |
| Popis: | Interleukin (IL)11 is a crucial regulator during the initiation of pregnancy in humans and mice. Elevated levels are detected in serum, placenta and decidua of women with pre-eclampsia. Elevated IL11 during placentation recapitulates pre-eclampsia in mice, although withdrawal rescues pre-eclampsia features, suggesting that IL11 could provide a novel therapeutic target. The aim of this study was to determine the safety profile of an IL11 antagonist ligated to polyethylene glycol (PEGIL11A) during pregnancy in mice. Blocking IL11 signalling during mid to late gestation pregnancy in mice did not affect pregnancy viability, or alter placental or fetal weight, or morphology. Importantly, decidual area remained unchanged. PEGIL11A did not affect maternal blood pressure, urinary protein or term pup weight. PEGIL11A administration to non-pregnant mice did not affect subsequent fertility; there was no difference in number of implantation sites, or placental or fetal weight between PEGIL11A and PEG-treated mice. These data show that blocking IL11Rα during placentation does not alter the placenta, decidua, fetus, maternal blood pressure or kidneys. These findings highlight the potential of IL11 signalling inhibition as a safe therapy to alleviate pre-eclampsia symptoms and demonstrate the potential for IL11 inhibition as a novel fertility-preserving therapy for women with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect